Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 701–702 | Cite as

HIPEC in the Elderly: A Meta-Analysis

  • Johan GagnièreEmail author
ASO Author Reflections



There are no conflicts of interest.


  1. 1.
    Gagniere J, Veziant J, Pereira B, Pezet D, Le Roy B, Slim K. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the elderly: is it reasonable? A meta-analysis. Ann Surg Oncol. 2018;25:709–19.CrossRefGoogle Scholar
  2. 2.
    Fagard K, Leonard S, Deschodt M, et al. The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: a systematic review. J Geriatr Oncol. 2016;7:479–91.CrossRefGoogle Scholar
  3. 3.
    Robinson TN, Eiseman B, Wallace JI, et al. Redefining geriatric preoperative assessment using frailty, disability and comorbidity. Ann Surg. 2009;250:449–55.Google Scholar
  4. 4.
    Alyami M, Lundberg P, Kepenekian V, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: a case-controlled, multicenter study. Ann Surg Oncol. 2016;23:737–45.Google Scholar
  5. 5.
    Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013;20:3497–503.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Digestive and Hepatobiliary SurgeryUniversity Hospital of Clermont-FerrandClermont-FerrandFrance
  2. 2.U1071 INSERMUniversité Clermont-AuvergneClermont-FerrandFrance

Personalised recommendations